BTC - BTC Health

[Ken]

Speculative Buy below 50 cents is the call on Westpac broking.

BTC is one of Australia's pure biotechnology investment funds. It offers retail investors exposure to a diversified portfolio of unlisted opportunities and listed companies. The big appreciation in value of R&D companies that occurs before and at the time of listing is generally not available to retail investors. Listed investee companies include Alchemia, Starpharma, Clinical Cell Culture, Prima Biomed and Phylogica. BTC is high risk, but could generate well-above average returns. Shareholders need to take a medium to long-term view.

The vast majority of investors will lose money in the biotech sector if they invest directly. BTC management has industry expertise and a wide information network that along with its ability to tap into unlisted companies provide it with a much better chance of generating attractive returns

Any opinions...

I like companies that give a lot of exposure.

Love ARGO investments that basically investments in the top companies...

Dont know a heap about BTC but would be keen to find out more.

 

[Crash]

Are they likely to have a dividend? How old is this stock?

 

[Ken]

done some research.

Dividend policy unsure of.

My thinking is also that if one of the companies that BTC invests in is the next big Biotech then chances are your a winner, as BTC will be a substancial holder, with the funds it invests now.

I also think BTC has not got much further to fall, as biotechs are undervalued and out of favour.

either way this is my long term stock that i hold for 20 + years. I am treating it like that rather than a specy, as it would appear its investing in the small end of the biotechs which i believe will grow.

Westpac broking has 18 month price target which is a positive

 

[Ken]

At the start of last week i set up a custom porfolio with all of BTC's holdings on my westpac broking account.

I just wanted to see whether the gains or losses of BTC's portfolio were being reflected in BTC's actual share price.

BTC's porfolio of shares gained 4.46% with the main stocks performing well:

CCE holdings gaining 20%
ACL gaining 9%.

It would appear this has been reflected in the share price with BTC also gaining.

BTC starting the week at .40 and closing and finishing at .415

With buyers at .42 and sellers at .425

I will be following this closely. I dont think BTC will be a mirror of its share portfolio performance, but its a very easy way to see how the company is performing, even on a daily basis.


Just a thought....

 

[Ken]

Hit 44 cents today. market depth looks to have swung in favour of holders.

Some big support around 40 cents. The company's porfolio is now over 8% up since I started tracking it and this has been reflected in the share price rising 8-10%.

I would be looking for weakness in BTC share price when its portfolio heads north with companies such as CCE and ACL gaining.

Its a long term hold for me, no one else seems interested but I like the theory of being able to have exposure to more than one biotech company, reduces risk, and returns are still potentially good long term if sentiment to the sector becomes favourable.

Who knows how things pan out, but if CCE cracks the big time, it will not only be CCE shareholders punching the air but BTC that has 26 million shares in them.

 

[TMC93]

Was just looking through the paper today, dividend yield of 114%? Surely this company is doing something ok but share price seems to disagree. Will have to look more into this company as im very light on in the Pharmaceuticals/Biotech sector. I also learnt from experience that i shouldnt buy shares based on Div % yield.

 

[System]

On December 4th, 2017, Biotech Capital Limited changed its name to BTC Health Ltd.

 

[Dona Ferentes]

BTC Health Ltd is a Pooled Development Fund which makes active investments in businesses that acquire, develop and distribute innovative medical products in Australia and New Zealand.

The company is building a group of high-growth businesses which together are focused on providing access to some of the best specialized therapeutics and medical devices from around the world.

BioImpact: invests in and holds intellectual property rights for pharmaceuticals and medical devices.

BTC Speciality Health: has recently expanded via the acquisition of the hospital infusion business (from Admedus Limited in FY2019). It commercialises and distribute the BTC health group's in-licenced pharmaceuticals and medical devices in the Asia/Pacific region.

Products: BTC has products like ambIT infusion pumps, catheters. It now has third party logistics and wholesaling arrangements in place and in June launched two dental products, CariSolv and PeriSolv into the Victorian market.

... sale of Bio101 Group Pty Ltd was completed on 31 July 2020 for cash consideration of $500,000 which represents a 500% return on BTC health’s initial investment in 2016, and is consistent with the valuation recognised in BTC health’s Net Tangible Asset backing as at 30 June 2020.

With Covid restrictions, business must be slow. It popped up on Naos (NCC) Key Portfolio Events 4Q2020:

• Elective surgery recommenced
• Landscape for a potential complementary acquisition increased
• Significant organic business progress – strategy to sell existing products within new markets segments

Has a NTA of 5c but selling closer to 10c. Market cap around $20mill. Run by 'medical entrepreneurs'

( DNH )

 

[frugal.rock]

Held BTC for a period last year when trading heavily. (Was kind to me despite it not being the kinda stock to trade short term.)
Has a solid connection with SIG if I remember correctly.
Thanks for the memory jog Dona.
Probably a good long term solid performer.
Chart showing it's due for some movement also.

 

[Dona Ferentes]

only a $20 million company.

One small cap investor (Naos) has faith:

BTC went into trading halt on the last day of June and the following day announced that it had agreed terms to acquire the exclusive distribution rights of the Mannitol portfolio of Pharmaxis (ASX: PXS). Even though the total consideration for these assets is only small ($2 million) we believe this is a highly strategic acquisition and may set BTC up for a transformational FY22.

Firstly, these products generate revenue of ~$1.50 million with gross margins of 45%. We believe that BTC will not need to increase their headcount to distribute these assets and hence the EBITDA margin will be significant, potentially enabling BTC to reach a breakeven position or better.

Secondly this gives BTC a foothold in the pharmaceuticals sector where they currently do not have any exposure, a factor we believe is key for any larger acquisitions or in licencing opportunities, where they will need to instill confidence that they can execute effectively within the pharmaceuticals space.

Finally, this is further confirmation that BTC can source deals internally and importantly execute on these from both a due diligence and a financing standpoint. Pleasingly, BTC also stated within their presentation materials that based on their unaudited financials, their revenue growth in FY21 should be circa +25% and looking forward they expect to grow at an organic revenue run rate in the mid-teens. We continue to believe that BTC has a significant amount of potential ahead and its unique offering and exposure to the healthcare industry will be closely followed by many. If FY22 is indeed the year when BTC can scale its current platform then we would expect it to be one of the strongest contributors to overall portfolio performance over the coming year.

 

[frugal.rock]

21 March 2022: Net Tangible Asset (NTA) Backing – February 2022

Company Current Value Cents per share
TOTAL 12,968,538 4.60c

Probably a good long term solid performer.

Ooh, history shows I've got that wrong for now but long term is open ended, right?!?

Very thinly traded (by Lucifer today?), big spreads. Eeugh.

A definite do your own research kind of stock. I don't know anything about it particularly anymore.
It looked attractive to me "once apon a time" though, thus it's in a watchlist.
No, it's not Bitcoin.
Only noticed it now as it's up 17% off an apparent $45 trade by some dastardly devil.

 

[Dona Ferentes]

Speculative Buy below 50 cents is the call - Westpac broking.

Yep, diversification only helps when they ALL don't go down.

now 1.6c (and a 36% drop today) on updated NTA.

 

[Dona Ferentes]

A definite do your own research kind of stock. I don't know anything about it particularly anymore.
.
No, it's not Bitcoin.

seem to be 'diversifying' into license and distribution mode?
.
Highlights:
- BioImpact granted exclusive sales and distribution rights to the Rhythm™ Evolution infusion pumps in Australia and New Zealand
- Comprehensive range of high-quality, electronic infusion pumps and administration sets
- Anticipated market introduction in 2024

Rhythm™ is a high-quality range of electronic, portable infusion pumps, administration sets and related
accessories, for use in both hospital and homecare applications. The pumps are Class11b re-usable medical devices for the continuous, and/or bolus administration of a wide range of therapeutic medicines, including post-operative pain management, obstetrics, antibiotic therapy, oncology and immunoglobulin infusions.

 

[Dona Ferentes]

and higher today... looks like earlier news baked in the rise

 

[Country Lad]

Highlights:
-
- Anticipated market introduction in 2024

Always difficult to judge if anything real is happening with these tiddlers. Could be over 6 months away from going to market, todays rush for shares is equivalent to about $7,000, but nearly half of the 324 mil shares tightly held but including NAOS Asset Management and Sigma Healthcare. hhmm.

 

[Dona Ferentes]

Always difficult to judge if anything real is happening with these tiddlers.

Highlights:
- BTC Cardio granted exclusive distribution rights to the ExoVasc® Personalised External Aortic Root Support (PEARS) medical device
- ExoVasc forecasted to generate sales revenue of approximately $700K in the first year, with planned annual growth of 10-15% pa

Wholly owned investee company, BTC Cardio Pty Ltd has entered into an agreement with Exstent Limited in the United Kingdom. (https://exstent.com), granting the company exclusive rights to sell and distribute its revolutionary medical device ExoVasc Personalised External Aortic Root Support.

ExoVasc is a novel, patented device, designed to manage aortic dilation in people with Marfan syndrome and related genetic conditions. The ExoVasc is placed around the ascending aorta where it provides support to the patient’s own aorta and aortic valve and is designed to prevent enlargement and rupture. This innovation developed by Exstent Limited sets a new standard in the surgical management of the dilated aorta. More than 1000 patients have now received their ExoVasc support and its effectiveness is proven by a total of over 3,000 patient-years’ experience gained since the first procedure in May 2004.

ExoVasc has been distributed in Australia since 2018 by Advanced Biomedical in Melbourne. Advanced has agreed to immediately transfer all rights and know-how to BTC Cardio. Under the terms of the transfer agreement, BTC Cardio will pay Advance a total consideration of up to $200,000, comprising $150,000 upon satisfactory completion of all transfer conditions, and up to a further $50,000 on the first anniversary depending on the attainment of agreed performance targets.
A total of 50 patients in Australia received an ExoVasc device implant in 2023, with a steady increase in the adoption rate of 10-15% per annum.

BTC Cardio will assume full responsibility for ExoVasc with immediate effect and is pleased to be a supporting sponsor of the Marfan and Aortopathy Conference in Brisbane on 20 April 2024.
.